MD Anderson Cancer: Novel Immunotherapy Combination Produces Durable Response in Frontline Metastatic Melanoma
July 14, 2021
July 14, 2021
HOUSTON, Texas, July 14 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 13, 2021:
* * *
Study shows 34.2% complete response rate for bempegaldesleukin plus nivolumab
* * *
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab is safe and produces a deep, durable response in . . .
* * *
Study shows 34.2% complete response rate for bempegaldesleukin plus nivolumab
* * *
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab is safe and produces a deep, durable response in . . .